TheraRadar
← Back
Data updated: Jun 28, 2026

ANNORA PHARMA

Generics
NeurologyImmunologyCardiovascular

ANNORA PHARMA is a generic drug manufacturer focused on Neurology, Immunology, Cardiovascular.

2002
Since
56
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

ANNORA PHARMA's Key Drugs

ANNORA PHARMA's core commercial portfolio centers on DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Neurology and Immunology — its most strategically important drugs approved in the last 15 years.

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM
Other

Esophagus Disease

Approved 2022
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE
Gastrointestinal
Approved 2017

ANNORA PHARMA's Recent FDA Approvals

ANNORA PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

ANNORA PHARMA's Therapeutic Areas

ANNORA PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 31%
5 drugs
Immunology 25%
4 drugs
Cardiovascular 19%
3 drugs
Gastroenterology 13%
2 drugs
Infectious Disease 13%
2 drugs

ANNORA PHARMA Pipeline Snapshot

Active clinical trials for ANNORA PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling